BIOMAT Database Logo BIOMAT Database Logo

Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. 2013

Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008559 Memantine AMANTADINE derivative that has some dopaminergic effects. It has been proposed as an antiparkinson agent. 1,3-Dimethyl-5-aminoadamantane,1-Amino-3,5-dimethyladamantane,Axura,D-145,D145,Ebixa,Memantin,Memantine Hydrochloride,Namenda,D 145
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
March 2010, Movement disorders : official journal of the Movement Disorder Society,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
June 1996, Neurology,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Levodopa-induced dyskinesia in Parkinson's disease.
March 2005, Journal of neural transmission (Vienna, Austria : 1996),
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease.
January 2017, Annals of Indian Academy of Neurology,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
July 2007, Current neurology and neuroscience reports,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Levodopa-induced ocular dyskinesia in Parkinson's disease.
October 2007, European journal of neurology,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
November 2022, Cells,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
On automated assessment of Levodopa-induced dyskinesia in Parkinson's disease.
January 2011, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
April 2008, The FEBS journal,
Edison I O Vidal, and Fernanda B Fukushima, and Adriana P Valle, and Paulo J F Villas Boas
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
July 2013, Movement disorders : official journal of the Movement Disorder Society,
Copied contents to your clipboard!